{"id":"liquid-formulation-of-hrv-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The liquid formulation contains HRV antigens or immunogenic components that trigger both humoral and cellular immune responses. By priming the adaptive immune system against HRV epitopes, the vaccine aims to prevent or reduce the severity of rhinovirus infections, which are among the most common causes of upper respiratory tract infections and can exacerbate asthma and other respiratory conditions.","oneSentence":"This vaccine stimulates the immune system to recognize and respond to human rhinovirus (HRV) antigens, providing protection against HRV infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:02.440Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of human rhinovirus infection"}]},"trialDetails":[{"nctId":"NCT06331156","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-03-22","conditions":"Gastroenteritis","enrollment":400},{"nctId":"NCT06025695","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-09-01","conditions":"Gastroenteritis","enrollment":2000},{"nctId":"NCT03954743","phase":"PHASE3","title":"Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-19","conditions":"Infections, Rotavirus","enrollment":1351},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT02141204","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-02-20","conditions":"Rotavirus","enrollment":451},{"nctId":"NCT02914184","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-27","conditions":"Infections, Rotavirus, Rotavirus Vaccines","enrollment":1612},{"nctId":"NCT00750893","phase":"","title":"Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-02","conditions":"Infections, Rotavirus","enrollment":3111},{"nctId":"NCT01171963","phase":"PHASE3","title":"Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-29","conditions":"Infections, Rotavirus","enrollment":3340},{"nctId":"NCT00363545","phase":"PHASE3","title":"To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-01","conditions":"Infections, Rotavirus","enrollment":1274},{"nctId":"NCT00382772","phase":"PHASE3","title":"A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11","conditions":"Infections, Rotavirus","enrollment":1200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Liquid formulation of HRV vaccine","genericName":"Liquid formulation of HRV vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to recognize and respond to human rhinovirus (HRV) antigens, providing protection against HRV infection. Used for Prevention of human rhinovirus infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}